Phase 1b Study of AMG 193, An MTA-Cooperative PRMT5i, Alone and in Combination with Other Therapies in MTAP-deleted NSCLC

被引：0

作者：

Spira, A. ^{[1
]}

Sacher, A. ^{[2
]}

Paz-Ares Rodriguez, L. ^{[3
]}

Felip, E. ^{[4
]}

Reguart, N. ^{[5
]}

Desar, I. ^{[6
]}

Punekar, S. ^{[7
]}

Dy, G. ^{[8
]}

Fontana, E. ^{[9
]}

Udagawa, H. ^{[10
]}

El Helali, A. ^{[11
]}

Menis, J. ^{[12
]}

Hummel, H. -D. ^{[13
]}

Itsara, A. ^{[14
]}

Eggert, T. ^{[14
]}

Besse, B. ^{[15
]}

机构：

[1] Virginia Canc Specialists, Fairfax, VA USA

[2] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] Hosp Doce Octubre, Madrid, Spain

[4] Vall dHebron Univ Hosp, Barcelona, Spain

[5] Hosp Clin Barcerlona, Barcelona, Spain

[6] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands

[7] NYU Langones Perlutter Hlth, New York, NY USA

[8] Roswell Park Comprehens Ctr Inst, Buffalo, NY USA

[9] Sarah Cannon Res Inst, London, England

[10] Natl Canc Ctr Hosp East Japan, Kashiwa, Chiba, Japan

[11] Queen Mary Hosp, Hong Kong, Peoples R China

[12] Univ Hosp Verona, Verona, Italy

[13] Univ Hosp Wurzburg, Wurzburg, Germany

[14] Amgen Inc, Thousand Oaks, CA USA

[15] Gustave Roussy, Orsay, France

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.12D.10

引用

页码：S350 / S350

页数：1

共 32 条

[21] TNG908, A BRAIN-PENETRANT MTA-COOPERATIVE PRMT5 INHIBITOR, IS EFFICACIOUS IN PRECLINICAL MTAP-DELETED MODELS INCLUDING GLIOBLASTOMA
Zhang, Minjie
Tsai, Alice
Cottrell, Kevin
Wilker, Erik
Davis, Charles
DiBenedetto, Heather
Weitzman, Ron
Huang, Alan
Maxwell, John
Briggs, Kimberly
NEURO-ONCOLOGY, 2023, 25
[22] Unbiased in vitro and in vivo drug anchor screens identify mechanisms of resistance and sensitization for MTA-cooperative PRMT5 inhibitors in MTAP-deleted cancer models
Lombardo, Steven
Tonini, Matthew R.
Grove, Lauren
Fenoglio, Silvia
Tepper, James
Shen, Binzhang
Stowe, Hannah
Liu, Shangtao
Meier, Samuel R.
Choi, Ashley H.
Khendu, Tenzing
Yu, Yi
Cottrell, Kevin M.
Maxwell, John P.
Andersen, Jannik N.
Huang, Alan
Briggs, Kimberly J.
Teng, Teng
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[23] PH020-2: an MTA-cooperative PRMT5 inhibitor with excellent selectivity and brain-penetration capability that targets MTAP-deleted tumors
Gao, Feng
Liu, Bin
Wang, Jing
Jing, Liandong
Wu, Yongyong
Zhang, Pengzhi
Gao, Yu
Li, Zhizhong
Guo, Yongqi
CANCER RESEARCH, 2024, 84 (06)
[24] The discovery and preclinical characterization of AMG 193, a first-in-class MTA-cooperative PRMT5 inhibitor with broad activity against MTAP-null cancers
Bojko-Matuszek, Agnieszka
Kolakowski, Damian
Bojko, Magdalena
Sowinska, Aleksandra
Mitula, Filip
Lacek, Krzysztof
Popiel, Delfina
Kwiatkowski, Sebastian
Kornatowski, Tomasz
Kliszcz, Beata
Jablonska, Anna
Flis, Krzysztof
Wiernicki, Bartosz
Wieczorek, Maciej
Pieczykolan, Jerzy
Abramczyk, Olga
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[25] Initial results from first-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in biomarker-selected solid tumors
Rodon, Jordi
Yamamoto, Noboru
Doi, Toshihiko
Ghiringhelli, Francois
Goebeler, Maria-Elisabeth
Fujuwara, Yutaka
Villalona-Calero, Miguel
Penel, Nicolas
Patnaik, Amita
Machiels, Jean-Pascal
Addeo, Alfredo
Abbruzzese, James
Postel-Vinay, Sophie
Rottey, Sylvie
Liu, Chunxu
Chuang, Chen-Hua
Kormany, William
Hughes, Paul
Keyvanjah, Kiana
O'Neil, Bert
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[26] Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors
Villalona-Calero, Miguel Angel
Patnaik, Amita
Maki, Robert G.
O'Neil, Bert
Abbruzzese, James L.
Dagogo-Jack, Ibiayi
Devarakonda, Siddhartha
Wahlroos, Sara
Lin, Chia-Chi
Fujiwara, Yutaka
Terbuch, Angelika
Postel-Vinay, Sophie
Goebeler, Maria-Elisabeth
Addeo, Alfredo
Prenen, Hans
Arkenau, Tobias
Sacher, Adrian G.
Liu, Chunxu
Kormany, William
Ahnert, Jordi Rodon
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[27] PRIMROSE: A modular phase 1/2a study of AZD3470, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP deficient advanced solid tumors.
Spira, Alexander I.
Lau, James
Hattersley, Maureen M.
Aronson, Boaz E.
Peters, Jane
Soo-Hoo, Yee
Sawant, Aarti
Loizou, Joanna
Smith, Claire
Dean, Emma
Postel-Vinay, Sophie
Solomon, Benjamin J.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[28] A PHASE 1B/2 UMBRELLA STUDY OF ANTI-PD-1 SASANLIMAB IN COMBINATION WITH OTHER THERAPIES FOR PATIENTS WITH STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC): THE LANDSCAPE 1011 TRIAL IN PROGRESS
Boyer, Michael
Patel, Sandip
Marron, Thomas
Pavlakis, Nick
Parakh, Sagun
Gadgeel, Shirish
Shafique, Michael
Hoyer, Robert
Camidge, D. Ross
Farber, Charles
Mehra, Ranee
Mekhail, Tarek
Blinman, Prunella
Kowalski, Karey
Davis, Craig
Pavlov, Dmitri
Gad, Nayra
Massarelli, Erminia
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A484 - A484
[29] A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101)
Hong, David S.
Yaeger, Rona
Kuboki, Yasutoshi
Masuishi, Toshiki
Barve, Minal A.
Falchook, Gerald Steven
Govindan, Ramaswamy
Sohal, Davendra
Kasi, Pashtoon Murtaza
Burns, Timothy F.
Langer, Corey J.
Puri, Sonam
Chan, Emily
Jafarinasabian, Pegah
Ngarmchamnanrith, Gataree
Rehn, Marko
Tran, Qui
Gandara, David R.
Strickler, John H.
Fakih, Marwan
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[30] Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101).
Hong, David S.
Strickler, John H.
Fakih, Marwan
Falchook, Gerald Steven
Li, Bob T.
Durm, Greg Andrew
Burns, Timothy F.
Ramalingam, Suresh S.
Goldberg, Sarah B.
Frank, Richard C.
Marrone, Kristen
Shu, Catherine A.
Gandara, David R.
Soman, Neelesh
Henary, Haby Adel
Govindan, Ramaswamy
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 →